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ABSTRACT
The aim of this study is to develop a sensitive HPLC method for the quantitative determination of cytisine in serum and to characterize 
the pharmacokinetic behaviour of cytisine after oral and intravenous administration in rabbits. The pharmacokinetic behaviour of 
cytisine is studied in male and female New Zealand rabbits after oral and intravenous administration. Cytisine is administered orally 
(dose of 5 mg/kg b.w.) under fasting condition (12 hours) and intravenously (dose 1 mg/kg b.w.) in the marginal ear vein. Cytisine 
serum concentrations are measured using a highly selective and sensitive validated HPLC method with UV detection. Linearity of the 
method is in the range 12–2 400 μg/L; accuracy and precision are both within ± 10%, and the limit of detection is 4 μg/L. Selectivity 
and stability are also validated. Basic pharmacokinetic parameters of cytisine after single oral and intravenous administration are calcu-
lated using TOPFIT software. Pharmacokinetic analysis suggests a rapid but incomplete absorption of cytisine after oral administration.
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The studies of cytisine pharmacokinetics in laboratory 
animals are rather old and insufficient. There are reports 
in literature on defining its pharmacokinetic behaviour 
after intravenous administration at a dose of 2 mg/kg 
b.w., and administration as a transdermal therapeutic 
system to rabbits (Sariev et al., 1999). Cytisine concen-
tration in blood is subjected to the laws of an open two-
compartmental pharmacokinetic model. Elimination is 
rapid with a half-life of 0.95 h. The short-term retention 
of cytisine in the body may be judged also from the mean 
residence time (MRT – 0.98 h) and total body clearance 
(Cltot – 2.4 L/h). Upon determination of kinetic behaviour 
of cytisine in mice, Klocking et al. (Klocking et al., 1985) 
found peak serum concentrations 2 hours after oral 
administration. The level of absorption is 42%. The high-
est cytisine concentrations are found in the liver, kidneys 
and suprarenal glands. Excretion is mainly with urine, 
where, 24 hours after intravenous and oral administra-
tion, 32% and 18% respectively of the dose is recovered. 
The half-life is 3 hours. Part of the administered cytisine 
is eliminated with the bile where the concentration of the 
substance is 200 times higher than blood concentration 
3–4 hours after intravenous, and 40 times higher – after 
oral administration. The concentration of unchanged 
cytisine in the feces is 3% 6 hours after intravenous and 
11% after oral administration (Klocking et al., 1985). 
The aim of this study is to develop a sensitive HPLC 
method for the quantitative determination of cytisine in 
Introduction
Tobacco smoking is the first avoidable cause of deaths and 
morbidity in developed countries (Mokdad et al., 2004). 
Smoking the leaves of Cytisus laburnum L. (golden rain 
tree) or Ulex europaeus is proposed for the treatment 
of tobacco dependence in 1955 (Lickint, 1956). T abex® 
is an original Bulgarian drug of plant origin, intended 
for treatment of nicotine dependence. The preparation 
is developed and introduced in 1964 on the basis of 
the alkaloid cytisine contained in the plant Laburnum 
anagyroides Medic. (Cytisus laburnum L.) fam. Fabaceae 
(Leguminosae) which is distributed in the southern parts 
of Central Europe and Italy (Dobreva et al., 2005). The 
largest quantity of the alkaloid – up to 3%, is found in 
the seeds. Cytisine possesses similar mechanism of 
action to that of nicotine. It excites autonomic nervous 
ganglia,  increases adrenaline release by the adrenal 
gland, stimulates the locomotor center and elevates arte-
rial blood pressure. Cytisine is readily dissolved in water. 
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serum and to characterize the pharmacokinetic behav-
iour of cytisine after oral and intravenous administration 
in rabbits. 
Materials and methods
Cytisine was kindly supplied by Sopharma 
Pharmaceuticals, Sofia, Bulgaria (Batch No 20205) (ana-
lytical certificate No 51/04.05.2005).
Quantitative analysis of cytisine in rabbit serum
Chemicals and Reagents
All solvents used for the HPLC mobile phase and extrac-
tion (water, acetonitrile, methanol, ethyl acetate) are of 
HPLC grade. All other reagents are obtained from Merck, 
Darmstadt, Germany, and phosphoric acid (85%) is pur-
chased from Janssen Chimica, Germany. Cytisine is pur-
chased from Sigma, and sulfanilamide obtained from the 
Bulgarian Drug Agency is used as internal standard. Stock 
and intermediate standards of cytisine and sulfanilamide 
are prepared in methanol. Calibration curve (CC) stan-
dards and quality controls (QC – low, middle and high) 
are prepared in advance in serum pools, are aliquoted for 
daily use, and are kept frozen below –20 oC until analysis. 
For the preparation of calibration and control samples 
a blank pool of commercial animal serum based quality 
control material is used. Calibration and control samples 
are prepared by mixing of definitive volumes (amounts) of 
intermediate solutions of cytisine, which are evaporated 
to dryness before the addition of the respective volumes 
of the serum pool. 
HPLC Assay 
Sample preparation 
To a 1.5 mL polypropylene tube are applied: 200 μL of 
serum, 50 μL of working internal standard solution (10 
mg/L of sulfanilamide in 0.5 M NaOH), 100 μL of satu-
rated solution of K2HPO4, and 500 μL of ethyl acetate/
acetonitrile mixture (1:1 by vol.); samples are extracted by 
reciprocating mixing for 20 min, centrifuged at 10 000 g 
for 5 min, organic supernatant is transferred to a second 
1.5 mL polypropylene tube and evaporated to dryness in 
a vacuum concentration centrifuge for 60 min at 40 °C. 
Residue is reconstituted with 100 μL of mobile phase, vor-
tex mixed for 15 sec., centrifuged at 10 000 g for 5 min, 80 
μL are transferred to 0.25 mL plastic auto-sampler insert, 
and 50 μL are injected for analysis. 
Chromatography and quantification
Chromatography is performed using a modular liquid 
chromatograph consisting of auto-sampler 717 plus, 
pump 515, column temperature device, photodiode 
detector 996 and a specialized chromatographic software 
Empower 32 (Waters Corporation, USA). Separation is 
achieved on a Hibar RP C18 column (Merck, Purospher 
STAR, 125 x 4 mm, 5 μm particles), with mobile phase 
consisting of acetonitrile/0.02 M phosphate buffer, pH 
3.0 (2/98 by volume, isocratic flow rate 1.1 mL/min, 
pressure 1  800 psi), and UV monitoring of the column 
effluent. Raw data of the chromatograms are collected 
and processed by Empower software at wavelengths from 
220 to 350 nm to assess component peak purities, and 
quantification is performed at the maximal absorbance of 
cytisine of 305 nm. All concentrations are calculated in 
internal standard mode with use of a sevenpoint calibra-
tion curve and cytisine/internal standard area ratio as a 
quantitative measure. 
Method validation strategy
The assay is completely validated using spiked animal 
serum samples, including selectivity, linearity, intra- and 
inter-day performance and stability, according to the 
industrial requirements (Bioanalytical method valida-
tion, 200 1 ). Pre-defined acceptance criteria are: 85 to 
115% accuracy and precision of the single determinations, 
no more than two different of six per run should have 
been out of range. QC-samples are used for calculating 
accuracy and precision within-run and between runs, 
as well as recovery of the extraction procedure and 
stability parameters of the method; 75% or a minimum 
of 6 standards, when back-calculated should have fallen 
within ± 15%, except for the lowest limit of quantification 
(LLOQ), when they should have been within ± 20%; one 
point with values falling outside these limits could be 
discarded (except for LLOD and upper limit of quantifica-
tion, ULOD calibration point), provided it did not change 
the established model. Acceptance criteria should always 
be assessed by comparing experimental concentrations 
against spiked (theoretical) concentrations.
Expe rimental animals
Male and female New Zealand rabbits (mean body 
weight 2.46 ± 0.75 kg) are kept under standard laboratory 
conditions (20 °С, humidity 60%, cycle – 12 hours light, 
12 hours dark), with unrestricted access to granulated 
standard food and water. The number of animals used for 
oral and intravenous administration is 8 and 10 rabbits 
respectively. The trial is performed in compliance with 
the requirements of European convention for the protec-
tion of vertebrate animals used for experimental and 
other scientific purposes (ETS123, 1991). 
Cytisine administration 
Intravenous administration (IV) 
Cytisine for intravenous administration is dissolved in 
sterile apyrogenic saline. Intravenous administration 
is performed in the marginal ear vein of the rabbits at a 
volume of 0.5 mL/kg b.w. (dose 1 mg/kg b.w.) with sterile 
disposable syringes and needles. 
Oral administration (PO) 
Cytisine is dissolved in tap water. By means of a plastic 
catheter the solution is administered directly into the 
stomach of the animal at a volume of 1 mL/kg b.w. (dose 
5 mg/kg b.w.) after an overnight fasting.
All cytisine solutions are prepared еx tempore.17
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Blood sampling and processing
Blood samples (volume 1–1.2 mL) are taken from the 
marginal vein of the other ear at the following intervals 
– immediately before administration and 0.083, 0.167, 
0.333, 0.5, 1, 2, 3, 4 and 6 hours after IV administration 
and, immediately before administration and 0.5, 1, 1.5, 2, 
3, 4, 6 and 8 hours after PO administration respectively. 
Total blood loss is 10–12 mL per animal. Forty minutes 
after withdrawal blood is centrifuged for 5 minutes at 
10  000 rpm (Еppendorf, MiniPlus centrifuge) to obtain 
0.4 – 0.5 mL serum. Serum is frozen at –20 °С until quan-
titative analysis of cytisine.
Calculation of pharmacokinetic parameters 
The pharmacokinetic parameters are calculated using 
TOPFIT (version 2.0) software: AUC0–∞ (μg*h/L), AUC0–t 
(μg*h/L), AUMC (μg*h2/L), Cltot (mL/min), Cmax (μg/L), 
Cs (μg/L), F (%), MRT0–t (h), MAT (h), t1/2 (h), Tmax (h), Vd 
(L and L/kg) applying a non-compartmental approach to 
the experimental cytisine concentrations in blood serum.
Statistical processing of results is performed with 
the help of MICROSOFT EXCEL 2000 software. Results 
are expressed as mean values ± SD and compared using 
Student-Fisher's t-test.
Results 
HPLC Assay Development
Chromatography. Cytisine and internal standard are 
baseline separated within 4.0 minutes and eluted in the 
form of symmetric peaks with no interference from bio-
logic matrix. Representative chromatograms are shown in 
Figure 1.
Selectivity is evaluated by analyzing blank samples 
(extracted without internal standard), and spiked samples 
at LLOQ level from five different sources of serum. For 
each source, the interference is evaluated by comparing 
the signal in blanks with the signal of the corresponding 
LLOQ spiked samples. For all blanks, cytisine and inter-
nal standard retention windows are free from endogenous 
interfering peaks. No serum matrix effect is observed 
under the described extraction procedure. 
Accuracy and precision are assessed via the analysis of 
QC samples at three levels in 6 independently processed 
batches. Within-run experiments are done together with 
the experiments for establishment of the LLOQ level for 
this method. Tables 1 and 2 represent the within-run 
results, between-run results of the accuracy and preci-
sion, as well as the LLOQ results.
Extraction recovery is determined by comparing the 
peak areas from the extracted QC samples with un-
extracted standards that represent 100% recovery. The 
extraction recovery of cytisine is constant for the tested 
concentration levels (QC low and QC high), averaging 62%. 
The linearity range is set between the LLOQ and 
the ULOQ representing the lowest and the highest con-
centration points of the established calibration curves. 
Calibration is performed with 7 standard points at 12.0 
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Figure 1. A: Zero sample chromatogram. B: Chromatogram of low 
quality control sample. C: Chromatogram derived of experimental 
study animal serum obtained one hour post dose.
Peak Name RT Area Height Amount Units
1 CYTISINE 2.799
2 Int. STD 3.297 30145 4232 1.000 μg/L
Peak Name RT Area Height Amount % Deviation Units
1 CYTISINE 2.850 2453 361 18.486 -7.57 μg/L
2 Int. STD 3.311 23093 3326 1.000 μg/L
Peak Name RT Area Height Amount Units
1 CYTISINE 2.866 9085 1359 162.378 μg/L
2 Int. STD 3.356 14685 2067 1.000 μg/L
A
B
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(LLOQ), 60.0, 120.0, 300.0, 600.0, 1200.0, and 2400.0 
(ULOQ) μg cytisine/L. Calibration curve is generated 
using the analyte to internal standard peak area ratios 
by weighted ( 1/x) least -squares linear regression. The 
calibration model is selected based on the analysis of the 
data by linear regression with/without intercepts and 
weighting factors (1/x, 1/x2 and 1/√x). The best fit for the 
calibration curve is achieved with the linear equation with 
a 1/x weighting factor. Original results and calibration 
plot of a calibration curve example are shown in Figure 2. 
The lower limit of quantification for cytisine , repre-
senting a signal to noise ratio of 10:1 is set at 12.0 μg/L. 
Results of the experiments validating LLOQ are presented 
in Table 1. Accuracy and precision are all within the 
acceptance criteria at this level. The mean response for 
cytisine peak at the assay LLOQ is about 10-fold grater 
than the mean response for the five blanks at the peak 
retention time. The limit of detection (LOD) for this 
m e t h o d  i s  a r o u n d  4 . 0   μ g / L  o f  c y t i s i n e  i n  e x t r a c t e d /
injected samples with mean response that is over 3-fold 
greater than the mean response for the five blank samples 
at the peak retention time. 
Stability studies. Freeze and thaw stability is deter-
mined after three freeze and thaw cycles each lasting 24 h. 
Quality control samples are extracted and analyzed after 
the third cycle (two levels in duplicate), and results are 
compared to the theoretical (spiked) values. Short-term 
stability is validated for 6 h and post-preparative stability 
is validated for 24 h, both at room temperature. Long term 
stability is evaluated by the analysis of quality control 
samples on three different occasions within 95 days. Stock 
solution stability is evaluated by direct analysis of the 
working standard in mobile phase on three different occa-
sions in the respective three months time frame. Results 
of the stability experiments are always well within ± 15% 
of deviation, and thus it is proven that no degradation of 
cytisine occurred under the conditions described.
Analysis of study samples started after the time of last 
blood sampling point of the experimental animals and is 
performed in several consecutive runs, each encompass-
ing its own calibration curve and set of QC samples. After 
completion of each chromatographic run chromatograms 
are inspected for correct integration without knowing the 
respective concentration. Concentrations of unknown 
Table 1. Within-run accuracy and precision for QC samples and LLOD QC sample.
 LLOD = 12.0
μg/L
  QC L = 20.0 
 μg/L
 QC M = 1081.0 
μg/L  
   QC H = 2162.16 
μg/L
C, μg/L d % C,μg/L d % C, μg/L d % C, μg/L d %
Sample 1 13.432 11.93 18.622 –6.89 1062.556 –1.71 2222.301 2.78
Sample 2 13.468 12.24 19.561 –2.19 1086.629 0.52 2197.365 1.63
Sample 3 12.824 6.87 19.420 –2.90 1085.081 0.38 2192.440 1.40
Sample 4 11.860 –1.16 20.750 3.75 1044.334 –3.39 2007.323 –7.16
Sample 5 11.499 –4.17 20.382 1.91 1083.234 0.21 2358.147 9.06
Sample 6 10.916 –9.03 19.123 –4.38 1042.450 –3.57 2145.089 –0.79
AVERAGE 12.333 19.643 1067.381 2187.111
SD 1.064 0.973 20.548 113.767
CV % 8.6 4.0 1.9 5.27
Table 2. Between-run accuracy and precision for QC samples.
  QC L = 20.0 
 μg/L
 QC M = 1081.0 
μg/L  
   QC H = 2162.16 
μg/L
Date C,μg/L d % C, μg/L d % C, μg/L d %
06.02.2006 19.123 –4.38 1042.450 –3.57 2145.089 –0.79
07.02.2006 18.486 –7.57 1065.534 –1.43 2144.737 –0.81
08.02.2006 20.091 0.45 1083.462 0.23 2196.527 1.59
09.02.2006 18.561 –7.20 1017.826 –5.84 2138.821 –1.08
10.02.2006 20.819 4.09 1100.598 1.81 2257.346 4.40
13.02.2006 19.598 –2.01 989.890 –8.43 2062.041 –4.63
AVERAGE 19.446 1049.960 2157.427
SD 0.909 41.537 65.224
CV % 4.7 4.0 3.0
2.00
0.00
6.00
4.00
8.00
10.00
0 200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400
A
r
e
a
 
R
a
t
i
o
Amount
Figure 2. Example calibration curve: plot and calculations obtained 
according to the method.19
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study samples are only calculated if results of CC and 
QC samples for each run met the pre-defined acceptance 
criteria.
Pharmacokinetics
Serum concentrations determined in the course of the 
trial are given in Tables 3 and 4 and Figures 3 and 4 for oral 
and intravenous administration of cytisine respectively. 
The pharmacokinetic behaviour of cytisine after oral 
and intravenous administration is evaluated. The values of 
the following pharmacokinetic parameters are calculated: 
Tmax, Cmax, AUC0–t, AUC0–∞, AUCt–∞, F, t1/2, Vd, Cltot, 
AUMC0–t and MRT0–t. (The values are given as means ± 
standard deviation).
Discussion 
Cytisine is among the oldest means to treat tobacco depen-
dence. After more than 40 years on the market, cytisine 
still is of considerable interest mainly because of its high 
efficacy and safety and low cost. Selective α4β2-nicotinic 
acetylcholine receptor ligands are important in the search 
for medicines for the treatment of tobacco dependence. 
Cytisine is an agonist of α4β2-nicotinic receptors with a 
high affinity for receptors (Ki = 0.45 nM) (Gonzales et 
al., 2006, Jorenby et al., 2006, Tonstad et al., 2006). There 
are data in the literature ( Coe et al., 2005, Imming et al., 
2001) suggesting that cytisine affinity for these receptors 
is 7 times higher than that of nicotine. 
Unfortunately cytisine pharmacokinetics in laboratory 
animals are scarce and disposition in man is practically 
not studied at all. This is the reason why the study of 
cytisine kinetics in animals is relevant. 
The developed HPLC analytical method for the assay 
of cytisine in blood serum is highly selective and sensitive. 
Linearity of the method is in the range 12–2  400  μg/L; 
accuracy and precision are both within ± 10%, and the 
limit of detection is 4 μg/L. It proves suitable for the pur-
pose of the study of cytisine pharmacokinetic behaviour. 
The ratio AUC0–t/ is less than 5% (4.46 ± 2.28) for the 
oral administration and less than 10% (9.24 ± 4.35) for 
Table 4. Serum concentration (mg/L) of cytisine after intravenous administration in rabbits (dose 1 mg/kg b.w.), (n = 10).
t (h) 0.0833 0.167 0.333 0.5 1.0 2.0 3.0 4.0 6.0
Rabbit I 1063.47 754.36 386.45 239.33 123.45 26.38 43.38 BDM BDM
Rabbit J 790.03 491.72 274.95 197.02 148.09 31.89 BDM BDM BDM
Rabbit K 680.34 570.97 301.94 229.01 125.02 24.53 BDM BDM BDM
Rabbit L 810.53 465.82 286.82 141.85 84.09 BDM BDM BDM BDM
Rabbit M 1282.30 526.09 345.66 222.36 127.14 30.14 29.65 BDM BDM
Rabbit N 504.15 232.30 136.37 99.54 39.29 BDM BDM BDM BDM
Rabbit O 417.78 303.56 169.64 108.42 44.74 22.28 BDM BDM BDM
Rabbit P BDM 629.29 336.45 196.15 140.32 22.72 BDM BDM BDM
Rabbit Q BDM 563.96 304.67 257.25 115.25 58.99 20.11 BDM BDM
Rabbit R 695.11 525.41 310.64 200.00 91.43 46.02 BDM BDM BDM
MEAN 780.465 506.348 285.358 189.093 103.883 37.503 31.048 – –
SD 282.367 150.168 77.064 54.631 38.006 13.041 11.699 – –
Table 3. Serum concentration (mg/L) of cytisine after oral administration in rabbits (dose 5 mg/kg b.w.), (n = 8).
t (h) 0 0.5 1.0 1.5 2.0 3.0 4.0 6.0 8.0
Rabbit A 0 592.77 375.26 180.14 109.96 85.43 28.90 BDM BDM
Rabbit B 01 4 6 . 3 8 1 0 0 . 8 6 1 3 1 . 5 1 5 9 . 4 9 4 2 3 . 3 9 8 7 . 9 7 B D M B D M
Rabbit C 0 411.51 315.84 137.51 64.702 37.08 14.35 BDM BDM
Rabbit D 0 563.66 425.13 229.36 152.08 73.06 52.46 BDM BDM
Rabbit E 02 4 5 . 6 3 2 5 9 . 1 2 1 5 3 . 2 1 7 5 . 0 5 3 9 . 9 8 1 4 . 3 2 B D M B D M
Rabbit F 04 0 9 . 8 0 2 7 7 . 2 8 1 5 2 . 3 3 8 4 . 2 5 4 5 . 7 5 1 5 . 5 3 B D M B D M
Rabbit G 0 538.87 246.48 214.87 98.01 24.87 15.70 BDM BDM
Rabbit H 0 188.95 151.94 113.05 72.83 49.40 14.98 BDM BDM
MEAN 0 387.196 268.989 163.997 89.547 47.371 30.526 – –
SD 175.191 107.243 40.929 30.323 21.900 26.712 – –20
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the intravenous administration. That proves that the time 
interval for measuring serum levels are properly chosen. 
Maximum serum concentrations after oral administra-
tion are observed within 35 minutes on the average, which 
suggests a rapid absorption of cytisine in gastrointestinal 
tract. Cmax is 388.9 ± 173.69 (μg/L). The rate of elimination 
of cytisine is relatively fast – the t1/2 is 51 min for the oral 
and 36 min for the intravenous administration. Sariev et 
al. (Sariev et al.. 1999) also found a half life of less than an 
hour (57 min) in the same animal model. The total body 
clearance found in our animal model (42.99  ±  23.6  mL/
min) after intravenous application is practically the same 
as the value found by the same authors – 40 mL/min.
The ratio F between AUC after oral and AUC 
intravenous administration (corrected for the dose) is 
32.18% suggesting an incomplete absorption or first pass 
metabolism. The knowledge of cytisine kinetics would 
prove useful for the development of new pharmaceutical 
formulations with modified release which could improve 
user’s compliance. 
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values (SD). Relative bioavailability F (%) after oral administration is cal-
culated by the equation: F = 100*AUCро/5*AUCiv
Parameter
Oral administration
Mean values (SD)
Intravenous administration
Mean values (SD)
Tmax (h) 0.59 (0.19) –
Cmax (μg/L) 388.89 (173.69) –
AUC0–t(μg*h/L) 542.80 (207.78) 319.68 (105.39)
AUC0–∞ (μg*h/L) 563.92 (211.15) 350.48 (111.99)
AUMC0–t (μg*h2/L) 707.96 (338.89) 189.20 (95.48)
MRT0–t (h) 1.30 (0.15) 0.56 (0.15)
t1/2 (h) 0.86 (0.17) 0.61 (0.19)
Vd (L) 13.06 (7.07) 2.55 (0.89)
Vd (L/kg) 6.21 (2.92) 1.02 (0.47)
Cltot (mL/min) 167.2 (64.68) 42.99 (23.60)
F0–∞ (%) 32.18 –
F0–t (%)  33.96 –
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Figure 3. Cytisine serum concentrations (Cs in μg/L) after oral 
administration in rabbits (dose 5 mg/kg b.w.) (mean values ± SD, 
n = 8).
Figure 4. Cytisine serum concentrations (Cs in μg/L) after intrave-
nous administration in rabbits (dose 1 mg/kg b.w.) (mean values ± 
SD, n = 10).